Bayer, Novartis and Teva topped February sales rankings in Russia

| By | Bayer, DSM Group, Medicinal Drug Prices, Novartis, TEVA

According to DSM Group, in February 2018, the commercial market of medicinal products amounted to 80.6 billion rubles (in retail prices). Compared to January 2018, the market volume increased by 4.0%. The sales grew by 4.8% compared to February 2017.

Compared to the same period of 2017, February 2018 was marked by a number of changes to the benefit of drugs in the high price segment of commercial drug market.

The share of expensive drugs was 38.6%, which is 1.7% more than in the previous year and 0.7% less than in January. In February 2018, 59.8% of medicines (in physical units) sold on the market were domestically produced, and they accounted for 31.8% of the market in value terms.

Prescription drugs represented 33.5% of the commercial market segment in February 2018 and 66.5% accounted for packaged over-the-counter drugs. In value terms, the market is almost divided in half (49% and 51%, respectively).

In terms of sales value, the company rankings for February 2018 were topped by Bayer followed by Novartis and Teva. In February 2018, Top 3 brands of medicines (in terms of pharmacy sales value) included such drugs as Ingavirin (0.9%), Kagocel (0.8%), and Nurofen (0.7%).